SHR7280,一种口服促性腺激素释放激素拮抗剂,用于控制性卵巢过度刺激中预防早发促黄体生成素峰:一项剂量探索2期试验
这项多中心、开放标签、剂量探索2期试验在85例不孕女性中评估口服GnRH拮抗剂SHR7280预防早发LH峰的最小有效剂量。结果显示200 mg每12小时为最小有效剂量,LH峰抑制率为100%(95%CI 92-100),胚胎和妊娠结局与300 mg每12小时组相当,治疗相关不良事件仅1例(1%,轻度)。
要点
- SHR7280 200 mg每12小时为预防早发LH峰的最小有效剂量。
- 200 mg每12小时组LH峰抑制率100%(95%CI 92-100),300 mg组100%(95%CI 91-100)。
- 200 mg每12小时组每例获卵数10.7±4.6,优质胚胎数3.9±2.6,临床妊娠率53%(95%CI 35-70)。
核心结论
- 口服GnRH拮抗剂SHR7280 200 mg每12小时是预防早发LH峰的最小有效剂量,且与高质量胚胎和高临床妊娠率相关,耐受性和安全性良好。
研究设计与样本
- 多中心、开放标签、剂量探索2期试验,于2022年1月26日至2023年8月3日纳入85例不孕女性。
- SHR7280起始剂量为300 mg每12小时,随后依次探索两个较低剂量组(200 mg每12小时和200 mg每24小时)。
- SHR7280从重组人FSH刺激第5天开始口服给药,直至hCG注射日。
主要发现
- 85例患者接受SHR7280:300 mg每12小时组n=40,200 mg每12小时组n=42,200 mg每24小时组n=3。
- SHR7280治疗平均(±SD)持续时间分别为5.7±1.2天、5.7±1.3天和3.7±0.6天。
- LH峰抑制率在所有患者中为99%(95%CI 94-100),300 mg每12小时组为100%(95%CI 91-100),200 mg每12小时组为100%(95%CI 92-100),200 mg每24小时组为67%(95%CI 9-99)。
- 200 mg每12小时组每例患者平均(±SD)获卵数、双原核受精卵数和优质胚胎数分别为10.7±4.6、6.9±3.2和3.9±2.6。
- 在200 mg每12小时组接受新鲜胚胎移植的患者中,62%(95%CI 44-78)血清β-hCG检测阳性,53%(95%CI 35-70)确认临床妊娠(每移植周期)。
关键数值与推荐
- 200 mg每12小时被确立为最小有效剂量。
- 300 mg每12小时组和200 mg每12小时组的胚胎学和妊娠结局相当。
临床怎么用
- 作者认为,口服GnRH拮抗剂可能是ART中预防早发LH峰的有效替代选择。
局限性
- 样本量中等,且无标准肽类GnRH拮抗剂作为对照组。
- SHR7280在特定人群(如卵巢储备减退患者和高OHSS风险患者)中的表现尚待确定。
- 尚需进一步研究以确定高BMI患者、计划冻胚移植患者以及使用GnRH激动剂触发患者中的推荐剂量。
- 研究仅纳入中国患者,且允许每次移植最多2枚胚胎。
- SHR7280在其他种族和地区的疗效和安全性需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the minimum effective dose of SHR7280, a novel oral GnRH antagonist, to prevent a premature LH surge in women undergoing controlled ovarian hyperstimulation for ART? SUMMARY ANSWER: SHR7280 at 200 mg once every 12 h (Q12h) was the minimal effective dose to suppress an LH surge and was associated with high-quality embryos, and a high clinical pregnancy rate. SHR7280 was well-tolerated and safe. WHAT IS KNOWN ALREADY: Currently, all approved GnRH antagonists for preventing a premature LH surge are injectable, peptide-based formulations, which can cause inconvenience and injection site reactions. There is a significant unmet need for an orally available GnRH antagonist to address this issue. SHR7280 has previously demonstrated effective suppression of LH levels in healthy volunteers in phase 1 trials. STUDY DESIGN, SIZE, DURATION: This multi-center, open-label, dosing-finding phase 2 trial was conducted between 26 January 2022 and 3 August 2023 in 85 infertile women. PARTICIPANTS/MATERIALS, SETTING, METHODS: The starting dose of SHR7280 was 300 mg Q12h, followed by dose exploration in two lower dose groups (200 mg Q12h and 200 mg Q24h) sequentially. Dose exploration was terminated if an LH surge occurred. SHR7280 was administrated orally starting on Day 5 of recombinant human FSH stimulation until hCG administration. The primary endpoint was the rate of premature LH surge inhibition during SHR7280 treatment. MAIN RESULTS AND THE ROLE OF CHANCE: Eighty-five patients received SHR7280: 300 mg Q12h, n = 40; 200 mg Q12h, n = 42; 200 mg Q24h, n = 3. The mean ( ± SD) duration of SHR7280 treatment was 5.7 ± 1.2, 5.7 ± 1.3, and 3.7 ± 0.6 days, respectively. The rate of LH surge inhibition was 99% (95% CI 94-100) in all patients, 100% (95% CI 91-100) in the 300 mg Q12h group, 100% (95% CI 92-100) in the 200 mg Q12h group, and 67% (95% CI 9-99) in the 200 mg Q24h group. Two hundred milligrams Q12h was established as the minimal effective dose. Embryological and pregnancy outcomes were comparable in the 300 and 200 mg Q12h groups. In the 200 mg Q12h group, the mean ( ± SD) number of oocytes retrieved per patient, two-pronucleate zygotes, and high-quality embryos was 10.7 ± 4.6, 6.9 ± 3.2, and 3.9 ± 2.6, respectively; among patients receiving fresh embryo transfer, 62% (95% CI 44-78) were tested positive for serum β-hCG and 53% (95% CI 35-70) were confirmed to be clinically pregnant per transfer. No spontaneous ovulation occurred on the day of oocyte retrieval. In all 85 patients, treatment-related adverse events were reported in 1 (1%; mild in severity) patient. LIMITATIONS, REASONS FOR CAUTION: The sample size was moderate and there was no standard peptide-based GnRH antagonist as a control group. Additionally, the performance of SHR7280 in specific populations, such as patients with diminished ovarian reserve and at high risk of OHSS, remains to be established. Further research is also needed to determine the recommended dose in patients with high BMI, intending for frozen embryo transfer, and using a GnRH agonist as trigger. Moreover, the study included only Chinese patients and allowed up to 2 embryos per transfer. The efficacy and safety of SHR7280 in other racial groups and regions require further investigation. WIDER IMPLICATIONS OF THE FINDINGS: Findings from this phase 2 trial suggest that an oral GnRH antagonist could be an effective alternative for preventing a premature LH surge in ART. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by Jiangsu Hengrui Pharmaceuticals. Z.L., Yu.S., C.S., Hong.C., and K.S. were employees of Jiangsu Hengrui Pharmaceuticals at the time of study. All other authors have no conflicts of interests to declare. TRIAL REGISTRATION NUMBER: NCT05082233.
引用
- Chi H, Song Y, Jin L, et al. SHR7280, an oral gonadotropin-releasing hormone antagonist, for the prevention of premature luteinizing hormone surge in controlled ovarian hyperstimulation: a dose-finding, phase 2 trial. Hum Reprod. 2025. PMID: 40373184. doi:10.1093/humrep/deaf082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。